A Study of Gilteritinib and Momelotinib in People with Acute Myeloid Leukemia (AML)

Full Title

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.

Protocol
25-283
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Aaron D. Goldberg
Co-Investigators
Eytan M. Stein
Diseases
Leukemia › Acute Myelocytic Leukemia
Leukemia › Acute Myelogenous Leukemia
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06235801
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description